The Billion-Dollar Molecule: The Quest for the Perfect Drug

by Barry Werth

Book Overview

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research.

Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing--atom by atom--both a new life-saving immunosuppressant drug, and a drug to combat the virus that...

• Format: Paperback
• Language: English
• ISBN: 0671510576
• ISBN13: 9780671510572
• Release Date: March 1995
• Publisher: Simon & Schuster
• Length: 464 Pages
• Weight: 0.80 lbs.
• Dimensions: 1.2" x 5.5" x 8.4"

Customer Reviews

difficult, fascinating, and compelling birth of a company

This is the story of the first few years of Vertex, a bioventure that sought to create drugs that were constructed molecule by molecule - it is supposed to be "rational drug design". In exchange for allowing the company to check his work for accuracy and proprietary disclosures, Werth was admitted into the inner circle of the company, with both executives and scientists, for four years. Werth offers masterful descriptions of both the science and the intricacies of the busisess deals. The work is similar to that of Tracy Kidder in "The Soul of a New Machine" and, in my opinion, of the same quality. At the center of the story is Vertex's founding visionary, Joshua Boger, formerly a researcher at Merck. He reasoned that instead of screening soil samples and insect secretions in a hot or miss approach in thousands of petri dishes, he could design drugs atom by atom to bind to - and thus inactivate - molecules instrumental to the disease process. In theory, these drugs would be without side effects: because of the precision of the design, they would adhere to their target alone, allowing beneficial enzymes of other chem reactions to go on unimpeded. Boger's first target molecule was FKBP, which he believed was a crucial agent of the immune system. By blocking it, he hoped to prevent the host's body from rejecting transplanted organs. While Boger was out raising money (eventually reaching $60 million), Vertex's researchers hunkered down to isolate and analyze FKBP, whose molecular mechanic remained poorly understood. Unfortunately, what happened is a great example of the difficulties in marrying business to cutting-edge science: after over two years of pushing themselves to the brink of nervous collapse, Vertex scientists found difficulties with FKBP. Even worse, Boger's arch rival, a prof at Harvard, discovered why. The prof beat VErtex, Werth argues, because he remained outside the venture capital game and could thus concentrate totally on the science and could openly collaborate with them rather than hide proprietary results. Nonetheless, driven and confident as ever, Boger turned his scientific team onto the new problem. Thru all of this, Boger comes off as a fascinating character: the son of a suicide, he is unshakably convinced that he can bend nature as well as the business world to his will. The reader sees what lies behind the herculean efforts of him and his team. Warmly recommended as a rivetting tale of human endeavor that embraces the true complexity.

A excellent cross between business text and fiction

I read this book a couple of years ago and enjoyed it very much. Over time I have forgetten about it. But lately I've been doing research into new business creation and remembered this well written book. Many of the dry lessons of academic research are presented in a case study that reads like fiction.

Excellent book, vivid insights into biotech hustle

A well-told, vivid story about real life drug development, executed with a sharp observer's eye and an even hand. Hardly a gushing account of medical miracles in the making, but by no means industry bashing either. Rather, an inside look at real people in a fascinating world. This book never quite got the critical acclaim that it deserved.

Fast-paced and Insightful

I first read this book nearly two years ago as research for a novel I was writing. Recently, I turned to it once more to pick up a few terms and found myself reading chapter after chapter! This non-fiction tale has enough twists and turns and drama to match any thriller on the market. An informative and engaging tale of a pharmaceutical start-up and the people involved. Joshua is interesting enough that the book could have been solely about him, but he isn't the only one. All of the players in this ego-driven mega-drama are interesting on many levels. Who would I reccomend this book to? Anyone who likes a well-told story. A background in medicine is not needed, and neither is a knowledge of business practices. All you need to enjoy this book is a brain . . . and a night light because you'll be reading this book deep into the night.

Extraordinary look into the world of Big Pharma

Barry's Werth spent several years with the scientists and bio-venturers who formed Vertex Pharmaceuticals. The work paid off in an insightful and entertaining book. The Billion Dollar molecule is the holy grail of the researchers in today's pharmaceutical world, and this book shows how they go about attaining it. A remarkably easy book to read even if you don't know a protein from a Springsteen. The reader can find something valuable from all angles. Read it as a science book, a thriller, a business narrative, or a straight novel, you'll find delight here.